YING-CHUN SHENNicholas, AlanAlanNicholasTSUNG-HAO LIUSoyama, AkihikoAkihikoSoyamaChen, Tse-ChingTse-ChingChenEguchi, SusumuSusumuEguchiCHANG-TSU YUANYoshizumi, TomoharuTomoharuYoshizumiItoh, ShinjiShinjiItohNakamura, NoriakiNoriakiNakamuraKosaka, HisashiHisashiKosakaKaibori, MasakiMasakiKaiboriIshii, TakamichiTakamichiIshiiHatano, EtsuroEtsuroHatanoOgawa, ChikaraChikaraOgawaNaganuma, AtsushiAtsushiNaganumaKakizaki, SatoruSatoruKakizakiCheng, Chih-HsienChih-HsienChengLin, Po-TingPo-TingLinSu, Yung-YehYung-YehSuWu, Chi-JungChi-JungWuWang, Hung-WeiHung-WeiWangRau, Kun-MingKun-MingRauHuang, Yi-HsiangYi-HsiangHuangCHIEN-HUAI CHUANGLI-CHUN LUHernandez, SairySairyHernandezLin, Shi-MingShi-MingLinFinn, Richard SRichard SFinnKudo, MasatoshiMasatoshiKudoCHIH-HUNG HSUANN-LII CHENG2024-10-112024-10-112024https://scholars.lib.ntu.edu.tw/handle/123456789/721957Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors.The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated.In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% 16.7%, = .034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors.Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.en[SDGs]SDG3journal article10.1200/JCO.24.0064539197119